Randomized, Open-label, Controlled Multicenter Study to Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in Chinese NSCLC Patients Harbouring Activating EGFR Mutations(Artemis)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Jul 2018
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2017 Planned End Date changed from 1 Jun 2021 to 1 Jun 2019.